---
title: Thyroid Drugs
type: content
phase: 1
status: complete
priority: high
tags: [thyroid, levothyroxine, hypothyroidism, hyperthyroidism, methimazole, PTU, thyroid-hormone]
created: 2025-11-08
last_modified: 2025-11-08
---

# Thyroid Drugs

## Introduction

Thyroid disorders are among the most common endocrine conditions, affecting thyroid hormone production and metabolism. Understanding thyroid pharmacology is essential for managing hypothyroidism (underproduction) and hyperthyroidism (overproduction) effectively.

## Thyroid Physiology

### Thyroid Hormone Synthesis

**Hypothalamic-Pituitary-Thyroid Axis**:
1. **Hypothalamus** → TRH (thyrotropin-releasing hormone)
2. **Anterior pituitary** → TSH (thyroid-stimulating hormone)
3. **Thyroid gland** → T4 (thyroxine, 93%) and T3 (triiodothyronine, 7%)

**Synthesis Steps**:
1. **Iodine uptake**: Na+/I- symporter (NIS) actively transports iodide into thyroid
2. **Oxidation**: Thyroid peroxidase (TPO) oxidizes I- → I2
3. **Organification**: TPO adds iodine to tyrosine residues on thyroglobulin
   - MIT (monoiodotyrosine), DIT (diiodotyrosine)
4. **Coupling**: TPO couples iodotyrosines
   - MIT + DIT → T3
   - DIT + DIT → T4
5. **Storage**: In colloid as thyroglobulin
6. **Release**: Proteolysis → T3, T4 released into blood

**Peripheral Conversion**:
- **80% of T3 from peripheral T4 → T3 conversion** (liver, kidney)
- **5'-deiodinase** (D1, D2) converts T4 → T3
- **T3 is active hormone** (3-4x more potent than T4)
- T4 is prohormone (longer half-life, more stable)

### Thyroid Hormone Actions

**Mechanism**: Nuclear receptors (thyroid hormone receptors - TR)
- Bind T3 (mainly) → gene transcription

**Effects**:
- **Metabolic**: ↑Basal metabolic rate, ↑O2 consumption, ↑heat production
- **Cardiovascular**: ↑HR, ↑contractility, ↑cardiac output
- **Developmental**: Essential for brain development (infancy), bone growth
- **Metabolic substrates**: ↑Gluconeogenesis, ↑glycogenolysis, ↑lipolysis, ↑protein synthesis and degradation

---

## Drugs for Hypothyroidism

### Thyroid Hormone Replacement

#### Levothyroxine (Synthroid, Levoxyl)

**Structure**: Synthetic T4 (L-thyroxine)

**Mechanism**:
- Replaces deficient T4
- Converted to active T3 peripherally (like endogenous T4)

**Why T4, Not T3?**:
- **Longer half-life** (7 days vs. 1 day) → once-daily dosing, stable levels
- **Physiologic**: Mimics normal T4 → T3 conversion
- **Safer**: Less cardiac stress (gradual conversion)

**Pharmacokinetics**:
- **Oral** (tablet)
- **Absorption**: 60-80% (small intestine)
  - **Take on empty stomach** (30-60 min before breakfast) - food ↓absorption
- **Protein binding**: High (>99% - TBG, albumin, transthyretin)
- **Half-life**: 7 days (allows once-daily dosing, steady state in 4-6 weeks)
- **Metabolism**: Peripheral deiodination → T3

**Clinical Uses**:
1. **Hypothyroidism** (primary, secondary) - **drug of choice**
2. **Thyroid hormone suppression** (thyroid nodules, thyroid cancer)
3. **Myxedema coma** (IV levothyroxine)

**Dosing**:

**Adults**:
- **Start**: 1.6 mcg/kg/day (~100-125 mcg for average adult)
  - Lower in elderly, cardiac disease: 25-50 mcg/day
- **Titrate**: Check TSH in 6-8 weeks, adjust by 12.5-25 mcg
- **Goal**: Normalize TSH (0.5-4.5 mIU/L)

**Special Populations**:
- **Elderly/Cardiac disease**: Start low (25-50 mcg), titrate slowly (risk: arrhythmias, angina, MI)
- **Pregnancy**: ↑Dose by 30-50% (↑TBG, ↑metabolism)
  - Check TSH every 4 weeks
  - Goal: TSH <2.5 (first trimester), <3.0 (second/third)

**Myxedema Coma**:
- **Medical emergency** (severe hypothyroidism)
- IV levothyroxine 200-400 mcg loading dose
- Supportive care, glucocorticoids

**Monitoring**:
- **TSH** (primary hypothyroidism): Goal 0.5-4.5 mIU/L
  - Check 6-8 weeks after dose change
  - Check annually once stable
- **Free T4** (if secondary hypothyroidism, monitoring therapy)

**Adverse Effects**:

**Overtreatment** (Hyperthyroidism symptoms):
- Tachycardia, palpitations, arrhythmias (atrial fibrillation)
- Tremor, nervousness, insomnia
- Weight loss, diarrhea
- Heat intolerance, sweating
- **Osteoporosis** (long-term overtreatment - suppresses TSH)
- **Angina, MI** (especially cardiac disease)

**Undertreatment** (Persistent hypothyroidism):
- Fatigue, weight gain, cold intolerance

**Drug Interactions**:

**↓Levothyroxine Absorption** (↓efficacy):
- **Calcium, iron supplements**: Take 4 hours apart
- **PPIs**: ↓Absorption (↑gastric pH)
- **Cholestyramine, colestipol**: Bind in GI tract (take 4 hours apart)
- **Sucralfate**
- **Soy products, fiber**

**↑Levothyroxine Metabolism** (↓levels):
- **CYP inducers**: Phenytoin, carbamazepine, rifampin, phenobarbital
- **Estrogen**: ↑TBG → ↑bound T4 → may need ↑dose

**↑Effect**:
- **Sympathomimetics**: Additive cardiac stimulation

**Contraindications**:
- Acute MI (relative - delay treatment or use low doses)
- Thyrotoxicosis (untreated)
- Adrenal insufficiency (treat first - thyroid hormone ↑cortisol metabolism)

**Clinical Pearls**:
- **Take on empty stomach** (30-60 min before breakfast)
- **Once-daily dosing** (long half-life)
- **Wait 6-8 weeks** to check TSH after dose change (steady state)
- **Consistent brand** recommended (bioequivalence varies)
- **Separate from calcium, iron** by 4 hours
- **Increase dose in pregnancy** (check TSH each trimester)
- **Start low in elderly/cardiac patients** (cardiac risk)

#### Liothyronine (Cytomel)

**Structure**: Synthetic T3 (L-triiodothyronine)

**Pharmacokinetics**:
- Oral, IV
- **Short half-life**: 1 day
- **Rapid onset**: Hours
- **No conversion needed** (already active T3)

**Clinical Uses**:
1. **Myxedema coma** (IV T3 + IV T4)
2. **Thyroid suppression test** (diagnostic)
3. Rarely: Hypothyroidism with poor T4 → T3 conversion (controversial)
4. **NOT routine replacement** (T4 preferred)

**Why Not Routine Use?**:
- **Short half-life** → multiple daily doses, fluctuating levels
- **Rapid cardiac effects** → ↑risk (palpitations, arrhythmias)
- **No physiologic advantage** (T4 adequately converted to T3)

**Dosing**:
- 25-75 mcg/day (divided BID-TID)
- Myxedema coma: 10-20 mcg IV q4-12h

#### Desiccated Thyroid (Armour Thyroid)

**Source**: **Porcine thyroid** extract

**Composition**: T4:T3 ratio ~4:1 (fixed ratio)
- vs. Human ratio 93:7 (predominantly T4)

**Issues**:
- **Variable T3 levels** → palpitations, fluctuations
- **Supraphysiologic T3** (higher than natural ratio)
- **Inconsistent potency** (natural product)

**Status**: **Not recommended** (ATA guidelines)
- Historical use only
- Levothyroxine preferred (consistent, physiologic)

**Note**: Some patients prefer (anecdotal), but no evidence of superiority

#### Liotrix (Thyrolar)

**Combination**: Synthetic T4 + T3 (4:1 ratio)

**Status**: Discontinued in US

### Therapeutic Monitoring

**Primary Hypothyroidism**:
- **Monitor TSH** (most sensitive)
- Goal: TSH 0.5-4.5 mIU/L (individual variation)
- Check 6-8 weeks after dose change, then annually

**Secondary Hypothyroidism** (pituitary/hypothalamic):
- TSH unreliable (deficient TSH production)
- **Monitor free T4** (goal: mid-normal to upper normal range)

**Overtreatment Signs**:
- **Suppressed TSH** (<0.1 mIU/L)
- Hyperthyroidism symptoms
- Atrial fibrillation (elderly)
- **Osteoporosis risk** (long-term TSH suppression)

---

## Drugs for Hyperthyroidism

### Thioamides (Antithyroid Drugs)

**Mechanism**: Inhibit thyroid peroxidase (TPO)
- Block **iodine organification** and **coupling**
- **↓Thyroid hormone synthesis**

**Note**: Do NOT affect already-synthesized hormone
- **Delayed effect** (weeks) - stored hormone must deplete

#### Methimazole (Tapazole)

**Structure**: Thionamide

**Mechanism**:
- **Inhibits TPO** → ↓T3, T4 synthesis
- **10x more potent** than PTU
- **Longer half-life** than PTU

**Pharmacokinetics**:
- Oral
- **Half-life**: 6-8 hours
- **Once-daily dosing** possible

**Clinical Uses**:
1. **Hyperthyroidism** (Graves' disease, toxic nodular goiter) - **preferred over PTU**
2. **Pre-operative** thyroid preparation (surgery)
3. **Before radioactive iodine** (RAI) therapy

**Dosing**:
- **Initial**: 10-40 mg/day (divided or once daily)
  - Mild: 10-20 mg/day
  - Moderate-severe: 30-40 mg/day
- **Maintenance**: 5-15 mg/day (after euthyroid)
- **Duration**: 12-18 months, then taper/discontinue (30-50% remission)

**Advantages over PTU**:
- **More potent** (10x)
- **Once-daily dosing** (better compliance)
- **Less hepatotoxicity** (PTU has Black Box Warning)
- **Preferred for Graves' disease**

**Adverse Effects**:

**Common (Mild)**:
- **Rash, pruritus** (5%): Usually resolves or switch to PTU
- GI upset, arthralgia
- Metallic taste

**Serious (Rare)**:

1. **Agranulocytosis** (0.2-0.5%):
   - **Life-threatening** (ANC <500)
   - Usually first 3 months
   - **Symptoms**: Fever, sore throat, infection
   - **Monitor**: **Baseline CBC, then if symptoms** (routine monitoring does NOT prevent - onset sudden)
   - **Stop drug immediately** if suspected → recovery usually complete

2. **Hepatotoxicity** (Rare):
   - **Less than PTU** (cholestatic pattern)
   - Monitor LFTs if symptoms

3. **Vasculitis** (ANCA-positive) (Rare)

**Teratogenicity**:
- **Category D** (not preferred in pregnancy)
- **Aplasia cutis** (scalp defects), choanal/esophageal atresia
- **PTU preferred in first trimester**
- **Can use in 2nd/3rd trimesters** (lower risk than PTU hepatotoxicity)

**Drug Interactions**:
- **Warfarin**: Antithyroid drugs ↓vitamin K-dependent clotting factors (disease effect)

**Clinical Pearls**:
- **Drug of choice for Graves' disease** (unless pregnancy first trimester)
- **Once-daily dosing** (compliance)
- **Watch for agranulocytosis** (fever, sore throat → stop drug, CBC)
- **No routine CBC monitoring** (sudden onset, not prevented)
- **Delayed effect** (weeks) - stored hormone depletes first

#### Propylthiouracil (PTU)

**Mechanism**:
1. **Inhibits TPO** (like methimazole) - less potent
2. **Inhibits peripheral T4 → T3 conversion** (5'-deiodinase) - unique to PTU

**Pharmacokinetics**:
- Oral
- **Short half-life**: 1-2 hours
- **Multiple daily doses** (TID-QID)

**Clinical Uses**:
1. **Pregnancy (first trimester only)** - preferred over methimazole
2. **Thyroid storm** (both mechanisms helpful)
3. Alternative if methimazole not tolerated

**Dosing**:
- **Initial**: 100-150 mg TID (300-450 mg/day)
- **Maintenance**: 50-150 mg BID-TID

**Advantages**:
- **Inhibits peripheral conversion** (T4 → T3) - useful in thyroid storm
- **Preferred in first trimester pregnancy** (less teratogenic than methimazole)

**Disadvantages**:
- **Multiple daily doses** (TID-QID) - poor compliance
- **Less potent** than methimazole
- **Hepatotoxicity** (Black Box Warning)

**Adverse Effects**:

**Similar to methimazole**: Rash, agranulocytosis (0.2-0.5%), vasculitis

**Unique**:
- **Hepatotoxicity** (More severe than methimazole):
  - **Black Box Warning**: Severe, sometimes fatal hepatitis
  - Usually first 6 months
  - **Monitor LFTs** at baseline, periodically
  - **Stop if ALT >3x ULN** or symptoms
  - Reason PTU is second-line (except pregnancy)

**Pregnancy**:
- **Preferred in first trimester** (methimazole teratogenic)
- **Switch to methimazole in second trimester** (lower hepatotoxicity risk)
- Crosses placenta less than methimazole (still crosses)

**Clinical Pearls**:
- **Second-line** (except pregnancy first trimester, thyroid storm)
- **Multiple daily doses** (short half-life)
- **Black Box Warning**: Severe hepatotoxicity
- **Inhibits T4 → T3 conversion** (useful thyroid storm)
- **Pregnancy**: Use first trimester, switch to methimazole in second

### Iodine and Iodide

**Mechanism** (High doses):
- **Wolff-Chaikoff effect**: High iodine → inhibits iodine organification (temporary)
- **↓Thyroid hormone synthesis** (short-term)
- **↓Thyroid vascularity** (reduces bleeding during surgery)

**Preparations**:
- **Potassium iodide (KI)** saturated solution (SSKI)
- **Lugol's solution** (iodine + potassium iodide)

**Clinical Uses**:
1. **Pre-operative thyroid preparation** (7-10 days before surgery):
   - ↓Vascularity → ↓bleeding
   - Must use **AFTER thioamide** (methimazole/PTU) to block new synthesis
2. **Thyroid storm** (acute management)
3. **Radioactive iodine protection** (nuclear disaster)

**Dosing**:
- SSKI: 1-2 drops TID (50-250 mg/day)
- Lugol's: 3-5 drops TID

**Limitations**:
- **Temporary effect** (escape phenomenon after 2 weeks)
- **Never use alone** (must combine with thioamide)
- **Never before thioamide** (will worsen - iodine substrate for synthesis)

**Adverse Effects**:
- Metallic taste, salivation
- GI upset
- Rash, acne
- **Iodism** (chronic toxicity): Brassy taste, GI symptoms

### Radioactive Iodine (RAI) - I-131

**Mechanism**:
- **β-particle emission** → destroys thyroid follicular cells
- **Selective uptake** by thyroid (Na+/I- symporter)
- **Permanent thyroid ablation**

**Pharmacokinetics**:
- Oral (capsule or liquid)
- Concentrated in thyroid
- **Half-life**: 8 days
- **Effect**: 2-3 months for full effect

**Clinical Uses**:
1. **Graves' disease** - **definitive treatment** (most patients eventually need)
2. **Toxic nodular goiter**
3. **Thyroid cancer** (post-thyroidectomy ablation, metastases)

**Advantages**:
- **Permanent cure** (high success rate ~80-90%)
- **Non-invasive** (no surgery)
- **Safe** (if not pregnant)

**Adverse Effects**:

**Common**:
- **Hypothyroidism** (expected, 80-90% of patients):
  - Usually develops within first year
  - **Lifelong levothyroxine replacement** required
- **Transient thyroiditis** (first weeks):
  - Pain, worsening hyperthyroidism (hormone release)
  - Treat with NSAIDs, β-blockers
- Metallic taste, xerostomia

**Rare**:
- **Worsening Graves' ophthalmopathy** (eye disease):
  - Pretreat with steroids in severe cases
- Thyroid storm (rare)

**Contraindications**:
- **Pregnancy** (destroys fetal thyroid) - **absolute contraindication**
- **Breastfeeding**
- **Confirm not pregnant** before giving

**Precautions**:
- **Avoid pregnancy** for 6-12 months after treatment
- **Radiation precautions** (avoid close contact with pregnant women, children for days)

**Clinical Pearls**:
- **Definitive treatment** for Graves' disease
- **Most patients become hypothyroid** → lifelong levothyroxine (expected)
- **Delayed effect** (2-3 months)
- **Absolutely contraindicated in pregnancy**
- **Stop thioamide 1 week before** (allows iodine uptake)

### Beta-Blockers

**Mechanism**: Block β-adrenergic receptors
- Do NOT affect thyroid hormone levels
- **↓Peripheral symptoms** of hyperthyroidism (sympathetic overactivity)
- **Propranolol**: Also blocks T4 → T3 conversion (additional benefit)

**Clinical Uses**:
1. **Symptomatic relief** (tachycardia, tremor, anxiety, palpitations)
2. **Bridge therapy** while awaiting thioamide effect
3. **Thyroid storm** (critical)

**Agents**:
- **Propranolol**: 20-80 mg q6-8h (preferred - blocks conversion)
- Atenolol, metoprolol (alternatives)

**Advantages**:
- **Immediate symptom relief** (unlike thioamides)
- **Well-tolerated** (short-term)

**Limitations**:
- **Does not treat underlying disease** (hormone levels unchanged)
- Contraindicated in asthma, severe COPD

**Clinical Pearl**: **First-line for symptom control** while waiting for definitive therapy

---

## Thyroid Storm (Thyrotoxic Crisis)

**Definition**: **Life-threatening** severe thyrotoxicosis with systemic decompensation

**Clinical Features**:
- **Hyperpyrexia** (>40°C)
- **Tachycardia** (often >140 bpm), atrial fibrillation
- **Altered mental status** (agitation, psychosis, delirium, coma)
- **GI symptoms** (nausea, vomiting, diarrhea, jaundice)
- **Heart failure**
- **Tremor, seizures**

**Precipitants**:
- Infection, surgery, trauma
- RAI treatment, thyroid palpation
- Medication non-compliance
- DKA, pregnancy

**Treatment** (Multidrug Approach):

**1. Block NEW Hormone Synthesis**:
- **PTU** 500-1000 mg loading, then 250 mg q4h
  - Preferred (inhibits synthesis AND peripheral conversion)
- OR Methimazole 60-80 mg loading, then 20 mg q4-6h

**2. Block Hormone Release** (1 hour AFTER thioamide):
- **Iodine** (SSKI or Lugol's): 5 drops q6h
  - Must give AFTER thioamide (or worsens)

**3. Block Peripheral Conversion** (T4 → T3):
- Already achieved by PTU (if used)
- **Glucocorticoids**: Hydrocortisone 100 mg IV q8h or dexamethasone 2 mg IV q6h
  - Also treats relative adrenal insufficiency

**4. Block Peripheral Effects**:
- **Propranolol** 60-80 mg PO q4-6h (or 1-2 mg IV q10-15min)
  - Titrate to HR <100 bpm
  - Also blocks T4 → T3 conversion

**5. Supportive Care**:
- **Cooling** (tepid sponging, cooling blankets) - avoid aspirin (↑free T4)
- **IV fluids** (aggressive rehydration)
- **Treat precipitant** (infection, etc.)
- **ICU monitoring**

**Clinical Pearl**: **"Block-release-convert-effect" sequence** - PTU → Iodine → Steroids → Propranolol + supportive

---

## Comparison: Hyperthyroidism Treatments

| Feature | Thioamides | RAI | Surgery |
|---------|------------|-----|---------|
| **Mechanism** | ↓Synthesis | Destroy thyroid | Remove thyroid |
| **Remission rate** | 30-50% | 80-90% | 95-100% |
| **Time to effect** | Weeks | 2-3 months | Immediate |
| **Hypothyroidism** | Rare (during) | Expected (80-90%) | Expected (100%) |
| **Pregnancy** | PTU in 1st trim | Contraindicated | Safe (2nd trim) |
| **Major risk** | Agranulocytosis | Hypothyroidism | Hypoparathyroidism, RLN injury |
| **Recurrence** | Possible | Rare | Rare |

**Treatment Approach**:
- **First-line**: Thioamide (methimazole) 12-18 months, then d/c → 30-50% remission
- **If relapse**: RAI (most patients) OR surgery
- **Surgery indications**: Large goiter, compressive symptoms, pregnancy (2nd trimester), patient preference
- **RAI contraindicated**: Pregnancy, breastfeeding

---

## Clinical Pearls

**Hypothyroidism**:
1. **Levothyroxine first-line** - synthetic T4, once-daily
2. **Take on empty stomach** - 30-60 min before breakfast
3. **Separate from calcium, iron** by 4 hours
4. **Monitor TSH** in 6-8 weeks (steady state)
5. **Start low in elderly/cardiac** disease - cardiac risk
6. **Increase dose 30-50% in pregnancy** - check TSH each trimester

**Hyperthyroidism**:
1. **Methimazole preferred** over PTU (once-daily, less hepatotoxicity)
2. **PTU in first trimester pregnancy** - less teratogenic
3. **Watch for agranulocytosis** - fever, sore throat → stop drug
4. **PTU has Black Box Warning** - severe hepatotoxicity
5. **β-blockers for symptom control** - immediate relief
6. **RAI definitive treatment** - hypothyroidism expected (lifelong levothyroxine)
7. **RAI contraindicated in pregnancy** - absolute
8. **Thyroid storm**: PTU → iodine (1h later) → steroids → propranolol + supportive

---

## Key Takeaways

1. **Levothyroxine**: Synthetic T4, drug of choice for hypothyroidism, once-daily, take on empty stomach
2. **TSH monitoring**: Check 6-8 weeks after dose change (7-day half-life → steady state)
3. **Drug interactions**: Calcium, iron, PPIs ↓absorption (separate by 4 hours)
4. **Methimazole**: Preferred thioamide, once-daily, agranulocytosis risk, PTU preferred in pregnancy (1st trimester)
5. **PTU**: Black Box Warning (hepatotoxicity), inhibits peripheral conversion, use first trimester pregnancy or thyroid storm
6. **Radioactive iodine (RAI)**: Definitive treatment, contraindicated in pregnancy, hypothyroidism expected (80-90%)
7. **Thyroid storm**: Medical emergency, multidrug approach (PTU, iodine, steroids, propranolol)
8. **β-blockers**: Symptom control only (does not affect hormone levels), propranolol blocks conversion
9. **Pregnancy**: PTU first trimester, switch to methimazole second/third trimester, increase levothyroxine dose
10. **Agranulocytosis**: Sudden onset (no routine CBC), stop drug if fever/sore throat

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. American Thyroid Association Guidelines for Management of Thyroid Disease
4. Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016.
5. Alexander EK, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017.
6. FDA Drug Safety Communications - Thyroid Medications
